Iradimed Appoints Joe Kiani as New Director

The latest update is out from Iradimed ( (IRMD) ).

On August 27, 2025, Anthony Vuoto retired from his position as a director of Iradimed Corporation and as chairman of the Compensation Committee for personal reasons, without any disagreements with the company. Following his retirement, Joe Kiani, a renowned medical technology innovator, was appointed on September 2, 2025, to fill the vacancy, maintaining the board size at five directors. Kiani, recognized for his expertise and leadership in medical technology, will serve as a member of the Audit Committee and chairman of the Compensation Committee, contributing to Iradimed’s growth in the medical device sector.

The most recent analyst rating on (IRMD) stock is a Buy with a $81.00 price target. To see the full list of analyst forecasts on Iradimed stock, see the IRMD Stock Forecast page.

Spark’s Take on IRMD Stock

According to Spark, TipRanks’ AI Analyst, IRMD is a Outperform.

Iradimed’s strong financial performance and positive earnings call sentiment are the primary drivers of its high score. Technical indicators suggest positive momentum, though caution is advised due to potential overvaluation and overbought signals. Corporate governance decisions further support the company’s strategic direction.

To see Spark’s full report on IRMD stock, click here.

More about Iradimed

IRADIMED CORPORATION is a leader in developing innovative MRI-compatible medical devices. The company designs, manufactures, markets, and distributes MRI-compatible medical devices, accessories, disposables, and related services. It is the only known provider of a non-magnetic intravenous infusion pump system specifically designed to be safe for use during MRI procedures.

Average Trading Volume: 55,757

Technical Sentiment Signal: Buy

Current Market Cap: $921.4M

Find detailed analytics on IRMD stock on TipRanks’ Stock Analysis page.